ATNM
Price
$1.25
Change
-$0.05 (-3.85%)
Updated
Nov 13 closing price
Capitalization
38.99M
10 days until earnings call
Intraday BUY SELL Signals
OXBDF
Price
$8.70
Change
-$0.00 (-0.00%)
Updated
Nov 6 closing price
Capitalization
971.19M
Intraday BUY SELL Signals
Interact to see
Advertisement

ATNM vs OXBDF

Header iconATNM vs OXBDF Comparison
Open Charts ATNM vs OXBDFBanner chart's image
Actinium Pharmaceuticals
Price$1.25
Change-$0.05 (-3.85%)
Volume$102.15K
Capitalization38.99M
Oxford Biomedica
Price$8.70
Change-$0.00 (-0.00%)
Volume$5.17K
Capitalization971.19M
ATNM vs OXBDF Comparison Chart in %
ATNM
Daily Signal:
Gain/Loss:
OXBDF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ATNM vs. OXBDF commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATNM is a StrongBuy and OXBDF is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (ATNM: $1.25 vs. OXBDF: $8.70)
Brand notoriety: ATNM and OXBDF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATNM: 52% vs. OXBDF: 202%
Market capitalization -- ATNM: $38.99M vs. OXBDF: $971.19M
ATNM [@Biotechnology] is valued at $38.99M. OXBDF’s [@Biotechnology] market capitalization is $971.19M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATNM’s FA Score shows that 0 FA rating(s) are green whileOXBDF’s FA Score has 0 green FA rating(s).

  • ATNM’s FA Score: 0 green, 5 red.
  • OXBDF’s FA Score: 0 green, 5 red.
According to our system of comparison, OXBDF is a better buy in the long-term than ATNM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATNM’s TA Score shows that 2 TA indicator(s) are bullish while OXBDF’s TA Score has 2 bullish TA indicator(s).

  • ATNM’s TA Score: 2 bullish, 6 bearish.
  • OXBDF’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, OXBDF is a better buy in the short-term than ATNM.

Price Growth

ATNM (@Biotechnology) experienced а -5.30% price change this week, while OXBDF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.64%. For the same industry, the average monthly price growth was -3.56%, and the average quarterly price growth was +66.73%.

Reported Earning Dates

ATNM is expected to report earnings on Nov 24, 2025.

Industries' Descriptions

@Biotechnology (+3.64% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OXBDF($971M) has a higher market cap than ATNM($39M). OXBDF YTD gains are higher at: 61.260 vs. ATNM (-0.794).
ATNMOXBDFATNM / OXBDF
Capitalization39M971M4%
EBITDA-43.43MN/A-
Gain YTD-0.79461.260-1%
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash59.9MN/A-
Total Debt1.29MN/A-
FUNDAMENTALS RATINGS
ATNM vs OXBDF: Fundamental Ratings
ATNM
OXBDF
OUTLOOK RATING
1..100
6349
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9994
PRICE GROWTH RATING
1..100
8537
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATNM's Valuation (64) in the Biotechnology industry is in the same range as OXBDF (79) in the null industry. This means that ATNM’s stock grew similarly to OXBDF’s over the last 12 months.

ATNM's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as OXBDF (100) in the null industry. This means that ATNM’s stock grew similarly to OXBDF’s over the last 12 months.

OXBDF's SMR Rating (94) in the null industry is in the same range as ATNM (99) in the Biotechnology industry. This means that OXBDF’s stock grew similarly to ATNM’s over the last 12 months.

OXBDF's Price Growth Rating (37) in the null industry is somewhat better than the same rating for ATNM (85) in the Biotechnology industry. This means that OXBDF’s stock grew somewhat faster than ATNM’s over the last 12 months.

OXBDF's P/E Growth Rating (98) in the null industry is in the same range as ATNM (100) in the Biotechnology industry. This means that OXBDF’s stock grew similarly to ATNM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATNMOXBDF
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
53%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
50%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
68%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
52%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
64%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
69%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
55%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
68%
View a ticker or compare two or three
Interact to see
Advertisement
ATNM
Daily Signal:
Gain/Loss:
OXBDF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SVACX6.58N/A
N/A
Federated Hermes Strategic Value Div C
LEQCX11.79-0.09
-0.76%
LoCorr Dynamic Opportunity C
MYITX10.26-0.11
-1.06%
NYLI WMC International Research Eq Cl A
MXEBX17.35-0.29
-1.64%
Empower Core Strategies US Eq Instl
HASGX14.96-0.46
-2.98%
Harbor Small Cap Growth Instl

OXBDF and

Correlation & Price change

A.I.dvisor tells us that OXBDF and IMMP have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OXBDF and IMMP's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OXBDF
1D Price
Change %
OXBDF100%
N/A
IMMP - OXBDF
23%
Poorly correlated
+2.79%
BDTX - OXBDF
21%
Poorly correlated
-7.80%
ATNM - OXBDF
21%
Poorly correlated
-3.85%
PRRUF - OXBDF
9%
Poorly correlated
N/A
PHGUF - OXBDF
9%
Poorly correlated
N/A
More